Chemotherapy regimens EVALUATION AND SIDE EFFECTS IN PATIENTS AT III colorectal cancer hospitals DR. Moewardi SURAKARTA
ABSTRACT: Colorectal cancer is one of the four most common cancer occuring in adult men and women and the third leading cause of cancer-related deaths in United States. Treatment modalities for colorectal cancer include surgery, radiotherapy, chemotherapy, and other targeted molecular therapies. Chemotherapy regimen in colorectal cancer patients was varied, in Indonesia there are many changes in the formulary that determine drug administration in colorectal cancer patients. We evaluated chemotherapy regimens which have given to stage III colorectal cancer patients, side effects appear after the administration of chemotherapy and the changes in Carcino Embryonic Antigen (CEA) levels in stage III colorectal cancer patients receiving chemotherapy. This was a descriptive study with cross sectional design and data were collected retrospectively. The inclusion criteria in this study were patients with a diagnosis of stage III colorectal cancer who had undergone surgical resection and received adjuvant chemotherapy in Moewardi General Hospital Surakarta for at least 8 cycles of chemotherapy. Evaluation by identifying chemotherapy regimens for stage III colorectal cancer patients and assess compliance with the management of therapy recommended by the National Comprehensive Cancer Network (NCCN) 2013 and also identification of the side effects. Evaluation of the changes in CEA levels performed in subjects that CEA baseline increased above 5 ng/ml and CEA data available in 2-4 months after the end of the last cycle of chemotherapy. Between January 2012 and August 2014 we retrospectively examined 43 patients with stage III colorectal cancer. Twenty three (53%) subjects received 5- fluorouracil leucovorin regimens and 5-fluorouracil oxaliplatin leucovorin (FOLFOX) which is the main regimens recommended by the NCCN were received in 20 subjects (47%). The regimens that given according to the management of therapy recommended by the NCCN 2013. The adverse events are peripheral neuropathy in 4 (9%) subjects who received FOLFOX regimen. In 5-FU/LV group, its adverse events were nausea and vomiting, occurs only in 2 (4%) subjects. Evaluation of the change in CEA level can only be performed in 11 subjects due to limited data on which three subjects (27,27%) showed a decrease in the value of CEA in the administration of chemotherapy.
